Posted by Michael Wonder on 30 Jul 2024
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion
30 July 2024 - Approval is based on data from two Phase 3 studies in branch and central retinal vein occlusion showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal drying with Vabysmo.
Roche announced today that the European Commission has approved Vabysmo (faricimab) for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch retinal vein occlusion or central vein occlusion).
